Stage I–II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH; International Agency for Research on Cancer; World Health Organization, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed Lyon (France): International Agency for Research on Cancer; 2008.
   Google Scholar
• Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258–2263.
   PubMed Web of Science ®Google Scholar
• Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174–181.
   PubMed Web of Science ®Google Scholar
• Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271–2281.
   PubMed Web of Science ®Google Scholar
• Persky DO, Li H, Stephens DM, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020;38(26):3003–3011.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Casasnovas R-O. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver? Blood. 2017;129(23):3059–3070.
   PubMed Web of Science ®Google Scholar
• Schöder H, Polley M-YC, Knopp MV, et al. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020;135(25):2224–2234.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Miller TP. The limits of limited stage lymphoma. J Clin Oncol. 2004;22(15):2982–2984.
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.
   PubMed Web of Science ®Google Scholar
• Illidge T, Specht L, Yahalom J, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.
   PubMed Web of Science ®Google Scholar
• Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652–669.
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Pollom EL, Khodadoust MS, et al. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys. 2015;92(1):99–106.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97–110.
   PubMedGoogle Scholar
• Stephens DM, Li H, LeBlanc ML, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 2016;34(25):2997–3004.
   PubMed Web of Science ®Google Scholar
• Freeman CL, Savage KJ, Villa D, et al. Long-term results of PET-guided radiation in advanced-stage diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2020. doi:https://doi.org/10.1182/blood.2020005846
   Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022.
   PubMed Web of Science ®Google Scholar
• Barraclough A, Alzahrani M, Ettrup MS, et al. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Adv. 2019;3(13):2013–2021.
   PubMed Web of Science ®Google Scholar
• Persky DO, Miller TP, Unger JM, et al. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015;125(2):236–241.
   PubMed Web of Science ®Google Scholar
• Grass GD, Mills MN, Ahmed KA, et al. Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations. Leuk Lymphoma. 2019;60(4):886–893.
   PubMed Web of Science ®Google Scholar
• Torka P, Kothari SK, Sundaram S, et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Adv. 2020;4(2):253–262.
   PubMed Web of Science ®Google Scholar
• Kamath SS, Marcus RB, Lynch JW, et al. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. Int J Radiat Oncol*Biol*Phys. 1999;44(3):563–568.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide. J Clin Oncol. 2012;30(28):3452–3459.
   PubMed Web of Science ®Google Scholar
• Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115–4122.
   PubMed Web of Science ®Google Scholar